Literature DB >> 16830057

Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.

E Kwiatkowska1, E Skasko, A Niwinska, A Wojciechowska-Lacka, J Rachtan, L Molong, D Nowakowska, B Konopka, A Janiec-Jankowska, Z Paszko, J Steffen.   

Abstract

The 1100delC germline mutation of the CHEK2 gene appears to contribute significantly to the overall breast cancer incidence in some West and North European countries, but seems to be much less frequent among breast cancer patients from other regions of Europe. In the present study we found, respectively, 3/487, 1/296 and 0/279 carriers of this mutation among breast cancer patients from the East-Central, South-East and West-Central regions of Poland. Two carriers of the 1100delC mutation were found among 120 patients with bilateral breast cancer, but only one had a previous family incidence of breast cancer. We found no carriers among 182 patients with unilateral breast cancer with family history of this tumor and among 64 patients with breast cancer and a second primary tumor at an other site. We conclude that the 1100delC mutation of the CHEK2 gene contributes little to the overall breast cancer burden in Poland, including familial cases of this malignancy. Further studies are still needed to evaluate the contribution of this mutation to the development of bilateral breast tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830057

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Genome-wide prediction of cancer driver genes based on SNP and cancer SNV data.

Authors:  Quanze He; Quanyuan He; Xiaohui Liu; Youheng Wei; Suqin Shen; Xiaohui Hu; Qiao Li; Xiangwen Peng; Lin Wang; Long Yu
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

2.  Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort.

Authors:  Aleksander Myszka; Pawel Karpinski; Ryszard Slezak; Halina Czemarmazowicz; Agnieszka Stembalska; Justyna Gil; Izabela Laczmanska; Damian Bednarczyk; Elzbieta Szmida; Maria Malgorzata Sasiadek
Journal:  J Appl Genet       Date:  2010-12-01       Impact factor: 3.240

3.  CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.

Authors:  Eswary Thirthagiri; Leng San Cheong; Cheng Har Yip; Soo-Hwang Teo
Journal:  Fam Cancer       Date:  2009-04-28       Impact factor: 2.375

4.  A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.

Authors:  Aneta Bąk; Hanna Janiszewska; Anna Junkiert-Czarnecka; Marta Heise; Maria Pilarska-Deltow; Ryszard Laskowski; Magdalena Pasińska; Olga Haus
Journal:  Hered Cancer Clin Pract       Date:  2014-04-08       Impact factor: 2.857

5.  The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population.

Authors:  Chaymaa Marouf; Omar Hajji; Brehima Diakité; Amal Tazzite; Hassan Jouhadi; Abdellatif Benider; Sellama Nadifi
Journal:  Springerplus       Date:  2015-02-01

6.  Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.

Authors:  L Mellemkjaer; C Dahl; J H Olsen; L Bertelsen; P Guldberg; J Christensen; A-L Børresen-Dale; M Stovall; B Langholz; L Bernstein; C F Lynch; K E Malone; R W Haile; M Andersson; D C Thomas; P Concannon; M Capanu; J D Boice; J L Bernstein
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.